FDA Inspection Intelligence
New Focus on Data Integrity and cGMP Compliance

Wednesday, March 7, 2018 · 1:30 p.m. - 3:00 p.m. EST

Drug and biologics makers are facing increased scrutiny of data integrity as an energized FDA deploys new tools to empower inspectors and concerns rise over Forms 483 and warning letters.

Mark I. Schwartz Esq. has seen it from the inside as former Deputy Director of OCBQ, CBER. Now in private practice, he advises clients like you on staying a step ahead of inspectors. Mark your calendar for 90 minutes mapping this new FDA crackdown, with fresh details on:

  • Background: Why the FDA is stepping up pursuit of data integrity issues now
  • The product adulteration threat: How FDA may invoke the FDASIA provision when companies balk at inspections
  • Sec. 704(a)(4): Why the agency may invoke this provision regarding advance request of records or in lieu of an inspection
  • The draft Quality Metrics initiative: Where it stands
  • And much more!

Here’s a rare chance to spend 90 minutes with an ex-insider still intimately involved with CBER inspections as a lawyer in private practice, and not pay a penny in sky-high hourly legal fees. So don’t delay. Sign up today.

Who Will Benefit

This session is appropriate for anyone concerned with quality and inspections at pharmaceutical and biologics facilities, including:

  • QA/QC
  • Regulatory/compliance
  • cGMP/manufacturing
  • Data analysis
  • Legal counsel

Webinar plus Audio Recording/Transcript
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus Audio Recording/Transcript
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

Audio Recording/Transcript
Learn more

$287

add to cart

 

 

 

Meet Your Presenter

Mark I. Schwartz Esq.

Director
Hyman, Phelps & McNamara

Mark I. Schwartz Esq., Director, Hyman, Phelps & McNamara, is the former Deputy Director of OCBQ, CBER. In a 13-year FDA career, Mr. Schwartz also worked closely CBER’s Division of Manufacturing and Product Quality and Division of Biological Standards and Quality Control, and served as Associate Chief Counsel of the FDA. Now in private practice, he advises clients on drug, biologic and device compliance, chemistry, manufacturing and control, and combination products, and has served as an expert witness in FDA-related litigation.

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone (703) 538-7600 | Fax (703) 538-7676 | Toll free (888) 838-5578 | Email customerservice@fdanews.com

© 2018 FDAnews